HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combining aspirin and proton pump inhibitors: for whom the warning bell tolls?

Abstract
Aspirin and clopidogrel are well-known antiplatelet agents that are widely used across the spectrum of cardio- and cerebrovascular disease. Upper gastrointestinal complications, including ulcer and bleeding, are relatively common during antiplatelet treatment and, therefore, many patients are also treated with a proton pump inhibitor (PPI). PPIs exert gastroprotection by raising intragastric pH. In recent years, it has been heavily discussed whether PPIs may reduce the cardiovascular protection by aspirin and, even more so, clopidogrel. Initially, pharmacodynamic and pharmacokinetic studies suggested a considerable drug interaction between PPIs and clopidogrel, and subsequent clinical studies were conducted to evaluate the clinical impact of this interaction. More recently, it has been reported that PPIs may also attenuate the antiplatelet effect of aspirin. This is particularly interesting, because a fixed combination of aspirin and a PPI (esomeprazole) has been developed and is currently under approval. Given the large number of patients taking aspirin and PPIs, even a small attenuation of the antiplatelet effect of aspirin may have substantial clinical impact. The present editorial summarizes current evidence on this drug interaction and discusses potential clinical implications.
AuthorsMorten Würtz, Erik Lerkevang Grove
JournalExpert opinion on drug metabolism & toxicology (Expert Opin Drug Metab Toxicol) Vol. 8 Issue 9 Pg. 1051-5 (Sep 2012) ISSN: 1744-7607 [Electronic] England
PMID22834712 (Publication Type: Editorial)
Chemical References
  • Platelet Aggregation Inhibitors
  • Proton Pump Inhibitors
  • Clopidogrel
  • Ticlopidine
  • Aspirin
Topics
  • Aspirin (adverse effects, therapeutic use)
  • Clopidogrel
  • Drug Interactions
  • Drug Therapy, Combination (methods)
  • Gastrointestinal Hemorrhage (etiology, prevention & control)
  • Humans
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Proton Pump Inhibitors (adverse effects, therapeutic use)
  • Ticlopidine (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: